General
Preferred name
SULFANILAMIDE
Synonyms
Sulphanilamide ()
UK-124 ()
P-aminobenzenesulfonamide ()
Sulfanilamida ()
Prontylin ()
Sulfamine ()
Aniline-p-sulfonic amide ()
Streptocid ()
Prontosil i ()
Sulphanilamidum ()
Avc ()
P-aminobenzenesulfamide ()
Sulfonamide ()
NSC-7618 ()
P&D ID
PD001658
CAS
63-74-1
102489-34-9
10103-15-8
Tags
available
drug
Approved by
FDA
First approval
1985
1965
Drug indication
bacterial disease
Bacterial infection
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Sulfanilamide is sulfonamide antimicrobial compound. It was first synthesized in 1908, but it was not until the 1930s that its antibacterial activity was discovered .
(GtoPdb)
DESCRIPTION
ulfanilamide (Sulphanilamide) is a potent and orally active sulfonamide antibiotic and can be a major intermediate of sulfamethoxazole biodegradation. Sulfanilamide also is a carbonic anhydrase inhibitor. Sulfanilamide shows inhibition on virus of lymphogranuloma venereum[1][2][3][4].
PRICE
29
DESCRIPTION
Sulfanilamide (UK-124) can competitively inhibit bacterial enzyme dihydropteroate synthetase with IC50 of 320 ??M.
DESCRIPTION
Sulfanilamide is a competitive inhibitor for bacterial enzyme dihydropteroate synthetase with IC50 of 320 μM.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Sulfanilamide is a competitive inhibitor for bacterial enzyme dihydropteroate synthetase, is a sulfonamide antibiotic. It is used for the treatment of vulvovaginitis caused by Candida albicans.
(Enamine Bioactive Compounds)
DESCRIPTION
Sulfanilamide (UK-124) can competitively inhibit bacterial enzyme dihydropteroate synthetase with IC50 of 320 μM.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
3
Compound Sets
26
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
47
Molecular Weight
172.03
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
1
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.08
TPSA
86.18
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
Microbiology/virology
Anti-infection
Member status
virtual
MOA
MEK1 Inhibitors
Carbonic anhydrase inhibitor
Target
CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4
antibiotic
Bacterial
DHPS
Indication
vulvovaginal candidiasis
Therapeutic Class
Antibiotics
Source data
